Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

16 April 2020
Uveal melanoma is a rare intraocular malignancy. Half of the patients diagnosed will develop metastases within 10 to 30 years, most commonly in the liver. Although there has been a significant development in the treatment of melanoma, no effective treatment to prevent or treat metastases of uveal melanoma is available. Oncolytic viruses are now being studied for various types of cancers and show promising results. Preclinical results show cytolytic activity of enteric cytopathic human orphan virus type 7 (ECHO-7) strain Rigvir in human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma and pancreas adenocarcinoma cell lines. The aim of this study was to test the possible cytolytic activity in human uveal melanoma cell lines.
3 uveal melanoma cell lines (Mel-202, MP41 and 92-1) and 2 concentrations of ECHO-7 virus Rigvir strain (MOI of 7 and 70 (1% and 10% (v/v), respectively) were used in the study. 2 concentrations of inactivated ECHO-7 virus strain were added (MOI of 7 and 70) as negative control. An equal volume of medium (without virus) was added to control cells. Cell proliferation was monitored for 96 hours.
The gained results suggest a cytolytic effect of Rigvir in all 3 uveal melanoma cell lines used in this study; the onset of the cytolytic activity varied between the cell lines.
Full article: https://bmcresnotes.biomedcentral.com/articles/10.1186/s13104-020-05068-4
PDF version:

Contacts for Media Inquiries

Rigvir Group
Address: Atlasa street 7C, Riga, Latvia, LV-1026
Phone: +371 67 716 132
E-mail: pr@rigvir.com